Release of prostaglandin D2 by murine mast cells: importance of metabolite formation for antiproliferative activity. by Haberl, C et al.
Release of prostaglandin D2 by
murine mast cells: importance of
metabolite formation for
antiproliferative activity
C. Haberl,
1,CA L. H¨ ultner,
2 A. Fl¨ ugel,
3 M. Falk,
1,2
S. Geuenich,
1 W. Wilmanns
1,2 and C. Denzlinger
4
1Medizinische Klinik III, Klinikum Grob hadern,
Ludwig-Maximilians-Universit¨ at, 
2GSF Zentrum f¨ ur
Umwelt und Gesundheit, D-81377 M¨ unchen,
3Max-Planck-Institut f¨ ur Psychiatrie, D-82152
Martinsried, and 
4Medizinische Klinik, Abteilung II,
Eberhard-Karls-Universit¨ at, D-72076 T¨ ubingen,
Germany
CACorresponding Author
Tel: (+ 49) 89 7095–1
Fax: (+ 49) 89 7095–8875
PROSTAGLANDIN (PG)  D2,  PGJ2 and  D
12-PGJ2 are  anti-
proliferative eicosanoids. We investigated the produc-
tion of PGD2 by murine bone marrow-derived mast
cells (BMMC) taking into consideration metabolism of
PGD2 to  PGD2 and  D
12-PGJ2.  PG-metabolites  were
quantified  by  high  performance  liquid  chromatog-
raphy  (HPLC)  combined  with  radioimmunoassay
(RIA).  Stimulated  with  calcium  ionophore  A23187
BMMC  released  eight-fold  more  PGJ2 and  D
12-PGJ2
than  PGD2.  Conversion  of  endogenously  produced
PGD2 to  PGJ2 and  D
12-PGJ2 proceeded  rapidly  in
contrast to metabolism of exogenously added PGD2.
The antiproliferative potency of these prostaglandins
is demonstrated in vitro. We conclude that determina-
tion of PGD2 production by mast cells must take into
consideration rapid conversion to active derivatives,
which  may  play  a  significant  role  in  growth
regulation.
Key words: Prostaglandin D2, Prostaglandin J2, D
12-Prosta-
glandin J2, Cyclopentenone, Anti-proliferative activity, Mast
cell
Introduction
Prostaglandin (PG) D2 and its metabolites PGJ2 and
D 12-PGJ2 are potent antiproliferative eicosanoids.1The
concentrations of PGD2, PGJ2 and D 12-PGJ2 required
for regulation of cell proliferation in vitro are in the
micromolar range.1 The high molar activity suggests
that  these  lipid  mediators  may  play  a  role  in  the
regulation of cell proliferation in vivo and that, on the
other hand, this principle may be used in anti-tumour
therapy.  In  fact,  the  related  chemically  stabilized
prostanoid  D 7-PGA1 has  been  proposed for  clinical
studies.2 PGD2 may also represent a component in
natural anti-neoplastic defence. Mast cells are regar-
ded as major sources of endogenous PGD2 produc-
tion. Murine bone marrow-derived mast cells (BMMC)
have been reported to produce 15–120pmol PGD2
per  million  cells  during  10–30min  of  incubation
following different kinds of stimulation.3,4 However,
these apparently low production rates of PGD2 are
unlikely to exert major biological effects in vivo.
We hypothesized that the reported PGD2 produc-
tion rates underestimate biosynthesis of this mediator,
because  PGD2 can  be  converted  to  other  active
metabolites  including  antiproliferative  PGJ2 and
D 12-PGJ2.  These  cyclopentenone  prostanoids  have
been shown to occur in aqueous media, blood plasma
and urine.1
In the present study PGD2 and its metabolites were
detected and quantified in supernatants from murine
mast  cells  by  combined  use  of  high  performance
liquid chromatography  (HPLC)  and radioimmunoas-
say (RIA) analysis. The antiproliferative potencies of
PGD2 and  its  derivatives  PGJ2 and  D 12-PGJ2 were
evaluated  testing  the  effect  of  these  PGs  on
[3H]-thymidine incorporation into human myelocytic
(HL-60),  monocytoid  (THP-1,  U937)  and  lymphoid
(Burkitt,  Raji) cell  lines  and on MTT-conversion by
murine bone marrow-derived mast cells (BMMC) and
IL-3-dependent and autonomous mast cell lines.
Materials and Methods
Chemicals
Unlabelled PGD2, PGJ2, D 12-PGJ2, LTC4, LTD4 and LTE4
were  from  Paesel  &  Lorei,  Frankfurt,  Germany,
5,6,8,9,11,12,14,15-[3H]-PGD2 (3,7  MBq/ml),  14,15-
[3H]-LTC4, -LTD4, -LTE4 (925kBq/ml), [1-14C]-arachi-
donic  acid  (AA)  (1,85  MB/qml),  PGD2-RIA-kit,
and  [methyl-3H]-thymidine  ([3H]-T)  (37  MBq/ml)
were  from  Amersham-Buchler,  Braunschweig,  Ger-
many.  Calcium-ionophore  A23187,  indomethacin,
4-hydroxy-2,2,6,6,-tetrametylpiperidine-l-oxyl (HTMP)
and gelatine from porcine skin (300 bloom) were from
Sigma, St Louis, MO, USA. 3-(4,5-dimethyl-2- thiazolyl)-
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Serva, Heidelberg, Germany. Fetal calf serum (FCS) and
RPMI 1640 were from Biochrom, Berlin, Germany. The
other chemicals  used were purchased from Merck,
Darmstadt, Germany and were at least of analytical
grade.
Cells and cell lines
Primary polyclonal BMMC were generated in cultures
of murine (BALB/c) bone marrow cells supplemented
with  pokeweed  mitogen-activated  spleen  cell-con-
ditioned  medium  (SCM)  as  previously  described.5
Briefly, murine bone marrow cells (1 3 105/ml) were
grown  in  RPMI-1640  medium  supplemented  with
20%  FCS,  20%  SCM,  2mM  L-glutamine,  100U/ml
penicillin-streptomycin  and  10–4 M  a -thioglycerol.
When propagating non-adherent bone marrow cells
in  this  culture  medium  with  weekly  refeeding,
homogenous  populations  of  mast  cells  could  be
obtained within a period of 3 to 8 weeks. Mast cells
used  for  analysis  of  eicosanoid  production  were
21–55 days ex vivo (33 ± 10 days; mean ± standard
deviation  (SD)).  IL-3-dependent  long-term  cultured
mast cell lines were derived from BMMC.5 A growth
factor independent malignant autonomous mast cell
line was derived from an IL-3-dependent long term
cultured mast cell line.6
A human myeloid leukaemic cell line (HL-60)7 was
cultured  in  RPMI  1640  containing  15%  FCS  and
100U/ml penicillin-streptomycin. Human monocytic
(THP-1)8 and  histiocytic  (U937)9 cell  lines  were
cultured in RPMI 1640 with 10%  FCS and 100U/ml
penicillin–streptomycin. Human Burkitt10 and Raji11
lymphoma  cell  lines  were  cultured  in  RPMI  1640
containing 10%  FCS and 100U/ml penicillin–strepto-
mycin.  HL-60-, THP-1-,  U937-,  Burkitt  and  Raji lym-
phoma cell lines were obtained from the American
Type Culture Collection (Rockville, MD, USA). Cells
were cultured at 37°C under humidified atmosphere
with 5%  (mast cells) or 10% CO2.
Determination of prostaglandin and leukotriene
production
For analysis of radioactive AA-metabolites 5 3 107 of
BMMC were prelabelled with [14C]-AA (18.5kBq/ml)
for 48h. Cells were washed twice and resuspended in
PBS (107 cells/ml) containing gelatine (0.5mg/ml) or
in culture medium (RPMI 1640 with 20%  FCS). After a
5-min period of preincubation, cells were incubated
with or without calcium ionophore A23187 (0.2m M)
at  37°C.  Incubation  was  stopped by centrifugation
(10min at 4°C and 600 3 g). For deproteinization
supernatant and pellet were seperated and added to 8
volumes of 90% aqueous methanol containing 0.5mM
EDTA and 1mM HTMP, pH 7.4. HTMP was used for
stabilization of lipid mediators. The suspensions were
stored at –40°C for at least 12h and then centrifuged
(20min at – 10°C and 9000 3 g). Supernatants were
evaporated  to  dryness  in  a  centrifuge  under  low
pressure (Speed Vac, Savant, Farmingdale, NY, USA)
and redissolved in 30% aqueous methanol containing
trace  amounts  of  unlabelled  PGD2,  PGJ2 and
D 12-PGJ2.
[14C]-AA-metabolites were seperated by HPLC per-
formed on a C18 Hypersil column (4.6 3 250mm,
5m m particles; Shandon, Runkorn, UK) with a C18
precolumn (Waters, Milford, MA, USA). The mobile
phase  consisted  of  methanol,  water,  acetic  acid
(65:35:0.1 by volume), pH 4.0 adjusted with ammon-
ium hydroxide. The flow rate was 0.4ml/min. After a
45min  period  the  methanol  concentration  in  the
solvent was gradually increased to 100% . Metabolites
were detected by liquid scintillation counting (HPLC
radioactivity  monitor  LB  507 A;  Berthold, Wildbad,
Germany).  [14C]-AA-metabolites  (PGD2,  PGJ2 and
D 12-PGJ2) were identified by comigration with unlab-
elled standards as detected at 220nm (Spectrophot-
ometer, Waters, Milford, MA, USA).
Analysis of prostaglandin and leukotriene produc-
tion  by  unlabelled  mast  cells  was  performed  by
sequential use of HPLC and RIA. BMMC were washed
twice and resuspended in PBS (0.5mg/ml gelatine) at
a  concentration  of  106 cells/ml.  Incubation  and
deproteinization were performed as described above.
Samples were redissolved in 30%  aqueous methanol
containing  trace  amounts  of  [3H]-labelled  PGD2 or
LTC4, LTD4 and LTE4 standards.
The  mobile  phase  of  HPLC  for  routine  prosta-
glandin analysis consisted of methanol, water, acetic
acid  (65:35:0.1  by  volume),  pH  4.0  adjusted  with
ammonium  hydroxide  (flow  rate:  0.4ml/min).  For
confirmation  of  the  identity  of  endogenously  pro-
duced PGD2 metabolites, additional solvent systems
were used: acetonitrile, water, acetic acid (40:60:0.1
by volume),  flow  rate:  0.4ml/min  and acetonitrile,
water and acetic acid (50:50:0.1 by volume), flow
rate: 0.5ml/min. The mobile phase for routine leuko-
triene analysis consisted of  methanol,  water, acetic
acid  (65:35:0.1  by  volume),  pH  5.6  adjusted  with
ammonium hydroxide (flow rate: 1.0ml/min). HPLC-
fractions  were  collected  in  0.5-min  intervals.  An
aliquot  of  these  fractions  was  counted  for  tritium
radioactivity  to  determine  retention  time  of
[3H]-standards. Another aliquot was stored at – 20°C
under argon for further analysis by RIA.
The commercial [3H]-PGD2-RIA (Amersham Buch-
ler, Braunschweig, Germany) of HPLC-fractions was
performed  as  described  by  the  manufacturer.  We
determined cross-reactivies of PGJ2- and D 12-PGJ2 to
be  7%  and  24%,  respectively.  The  [3H]-cysteinyl
leukotriene-RIA  was  performed  as  described
earlier.12
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Determination of metabolism of [
3H]-PGD2
Metabolism  of  [3H]-PGD2 to  [3H]-PGJ2 and
[3H]-D 12-PGJ2 was  determined  by  HPLC  following
incubation  of  [3H]-PGD2 (3.7kBq/ml)  for  0min  to
24h in phosphate buffered saline (PBS) or in culture
medium. Controls in PBS were performed with and
without BMMC (106 cells/ml) and with and without
gelatine (0.5mg/ml). Preparation of samples for HPLC
was performed as described for analysis of endoge-
nous  PG-production  including  the  deproteinization
procedure.  Retention  times  of  [3H]-PGD2 and  its
metabolites were established as described for analysis
of [14C]-AA metabolites.
Proliferation assays
Cells were incubated for 24h with or without PGD2,
PGJ2 and  D 12-PGJ2 at  concentrations  of  10nM  to
0.1mM.  [3H]-T  uptake  into  cells  was  used  as  a
parameter of DNA-replication and cell proliferation.
After 24h of incubation in the presence of [3H]-T in
microtitre  plates  (37kBq/well) cells  were collected
on  glassfibre  filters  by  a  cell  harvester  (Canberra-
Packard, Dreieich, Germany)  and radioactivity asso-
ciated with the washed and dried filters was quanti-
fied  with  a  Matrix  96  counter  (Canberra-Packard,
Dreieich, Germany) as b -counts. Alternatively, a col-
orimetric proliferation assay, the MTT-test, was used
as  described.5 Briefly,  cultured  cells  in  microtitre
plates were incubated for 4h with MTT . Incubation
was  stopped  with  acidified  isopropanol.  Optical
density  (OD)  was  detected  in  a  ELISA-reader  (SLT ,
Salzburg, Austria) at a test wave length of 550nm and
a reference wave length of 690nm. Results are shown
as OD 550–690 values.
Results
Mast cells release PGD2 that is rapidly
converted to PGJ2 and D 12-PGJ2
Following  labelling  with  [14C]-AA  and  stimulation
with  calcium  ionophore  A23187  BMMC  released
[14C]-AA  and  small  amounts  of  its  metabolites  co-
migrating  on  HPLC  with  LTC4,  PGD2,  PGJ2 and
D 12-PGJ2 (not  shown).  In  addition  a  number  of
unidentified metabolites were formed.
Release of unlabelled PGD2, PGJ2 and D 12-PGJ2 by
BMMC was quantified by combined use of HPLC and
RIA.  PGD2,  PGJ2 and  D 12-PGJ2 were  detected  in
samples stimulated with A23187 (0.2m M) for 30min
(Fig. 1). The total concentration of these mediators
amounted to 153.6 ± 78.4pmol/106 cells (n = 4) (Fig.
2). The relative quantities of PGD2, PGJ2 and D 12-PGJ2
were 11 ± 8% , 53 ± 18%  and 36 ± 17% (n = 4, mean
±  SD),  respectively  (Figs.  1  and  2).  The
A23187-stimulated  release  of  PGD2,  PGJ2 plus
D 12-PGJ2 was  169%  ±  14%  of  the  unstimulated
samples (n = 3, mean ± SD) (Fig. 2).
Importance of metabolite formation for antiproliferative activity
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FIG. 1. PGD2 and its metabolites detected by [3H]-PGD2-RIA in
HPLC  fractions  of  a  supernatant  of  BMMC.  BMMC  were
stimulated with calcium ionophore A23187 (0.2m M). Super-
natants were separated by HPLC and HPLC-fractions were
analysed by RIA. Retention times of authentic PGD2, PGJ2
and D 12-PGJ2 standards are indicated by arrows.
FIG. 2. Endogenous production of PGD2, PGJ2, D 12-PGJ2 and
of total of these prostaglandins (PGD2 + metab.) and of LTC4.
BMMC  were  suspended  in  PBS  with  (+)  or  without  (–)
calcium  ionophore  A23187  (0.2m M)  for  30min  at  37°C.
Results  are  given  as  mean  ±  SD  or  range  of  two  to  10
independent experiments (number in parenthesis).0 min 30 min 4 h 24 h
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The identity of PGD2, PGJ2 and D 12-PGJ2 released in
the  supernatant  by  BMMC  was  confirmed  by  co-
migration  with  authentic  [3H]-labelled  PGD2 and
authentic unlabelled PGD2, PGJ2 and D 12-PGJ2 with
varying mobile phases and flow rates as described in
the Methods section (data not shown).
PGD2 is spontaneously metabolized to PGJ2
and D 12-PGJ2
PGD2 was  metabolized  to  PGJ2 in  PBS.  Further
metabolism to D 12-PGJ2 occurred in culture medium
containing FCS (Fig. 3). Following 30min of incuba-
tion  in  PBS  or  culture  medium  19%  or  33%   of
[3H]-PGD2 were metabolized, respectively. The half-life
of PGD2 was more than 10h in PBS and 3h in culture
medium. Metabolism of extracellular PGD2 was not
altered in the presence of 106 BMMC per ml. Gelatine
(0.5mg/ml) had also no effect on PGD2 metabolism.
The procedures of sample preparation had no influ-
ence on recovery or metabolism of PGD2.
BMMC produce large amounts of LTC4
Following  30min  of  incubation,  BMMC  produced
85.4 ± 74.0pmol LTC4/106 cells (n = 10) and 42.1 ±
C. Haberl et al.
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FIG. 3. Metabolism of [3H]-PGD2 in PBS (A) and culture medium containing FCS (B). After incubation of [3H]-PGD2 in PBS or
culture medium, samples were processed as described in the Methods section. [3H]-PGD2 and its metabolites were detected
by continuous radiodetection in the HPLC eluate. [3H]-PGD2 (j ), [3H]-PGJ2 (m ) and [3H]-D 12-PGJ2 (d ) were identified by co-
migration with authentic unlabelled standards. [3H]-D 12-PGJ2 could only be detected in culture medium containing FCS.
Table 1. Concentrations of PGD2, PGJ2 and D 12-PGJ2 required for 50%  inhibition of cell proliferation (IC50) in selected cell lines
(n = 4)
Cell culture IC50 of
PGD2 PGJ2 D 12-PGJ2
HL-60-myelocytic cell line (human) 11µM 11.5µM 12µM
Primary bone marrow-derived mast cells (BMMC) (murine) 10µM 25µM 20µM
IL-3-dependent mast cell line (murine) 4µM 9µM 5µM
Autonomous mast cell line (murine) 4µM 11µM 6µM
THP-1 monocytic cell line (human) 50µM 50µM 30µM
U937 histiocytic cell line (human) 70µM 80µM 40µM
Burkitt lymphoma cell line (human) 2.5µM 3.5µM 5µM
Raji lymphoma cell line (human) 7µM 7µM 9µM20 10 4 2 0.6
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33.8pmol LTC4/106 cells (n = 5; mean ± SD) with and
without calcium ionophore A23187 (0.2m M), respec-
tively.  LTC4 was  not  metabolized  to  LTD4 or  LTE4
under the conditions used.
PGD2 and its derivatives PGJ2 and D 12-PGJ2
exert strong antiproliferative activity
PGD2 and its metabolites inhibited cell proliferation
in all in vitro models tested (Table 1, Fig. 4). The IC50
values varied between 2.5 and 80m M in different cell
types. PGD2, PGJ2 and D 12-PGJ2 were equally effec-
tive. At concentrations below 0.5m M, no significant
effect  on  cell  proliferation  was  observed.  Indom-
ethacin (0.1mM to 10nM) had no influence on the
proliferation of BMMC, TPH-1,  U937 or HL-60 cells
(Fig.  4).  PGD2 was  rapidly  metabolized  in  culture
medium  to  PGJ2 D 12-PGJ2 and  other  not  identified
metabolites or conjugates.
Discussion
Our  data  demonstrate  that  murine  BMMC  release
PGD2 and LTC4, potent eicosanoid mediators. PGD2
undergoes  immediate  metabolism  to  PGJ2 and
D 12-PGJ2 during production by BMMC (Fig. 1). This
rapid  metabolism  of  PGD2 is  not  explained  by
degradation in extracellular fluid, because the half-life
of PGD2 is more than 10h in PBS and 3h in culture
medium containing FCS. Mast cells do not contribute
to conversion of extracellular PGD2.
The total of PGD2, PGJ2 and D 12-PGJ2 produced by
stimulated mast cells is about eight-fold the amount of
PGD2 alone  (Figs  1  and  2).  Separation  of  PGD2-
metabolites is required prior to RIA, because consider-
able differences exist in the immunoreactivity of the
various  PGD2 metabolites  corresponding  to  very
different cross-reactivity profiles in radio-immunologic
analysis. Direct radio-immunologic analysis3 may thus
result in gross underestimation of the PGD2 produc-
tion  and  of  the  PGD2 mediated  antiproliferative
potential of BMMC. Stimulation of BMMC with A23187
significantly increased the release of PGD2, PGJ2 and
D 12-PGJ2 in total. This is largely due to an increased
release of the latter two metabolites (Fig. 2).
A number of peaks detected in the HPLC chromato-
gram  of  supernatant  or  pellet  of  [14C]-AA-labelled
BMMC have not yet been identified. Some of them may
represent further products derived from PGD2.1,13–15
Identification  of  these  metabolites  requires  more
efficient procedures to label BMMC with [14C]-AA.  The
respective experiments are under way.
In contrast to PGD2 LTC4 remained stable under the
conditions  investigated,  i.e.  in  serum-free  medium.
The  amounts  of  LTC4 produced  in  our  model  of
murine BMMC accord with data shown by Razin et
al.3 indicating that BMMC represent a reproducible
model for analysis of eicosanoid production.
Importance of metabolite formation for antiproliferative activity
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FIG. 4. Modulation of cell proliferation by PGD2 and by its
metabolites. Results obtained in a THP-1 monocytic cell line
(human) (A), a HL-60 myeloid leukemic cell line (human) (B)
and  a murine  autonomous  mast cell line (C) are demon-
strated. Results are expressed in percentage of control of
[3H]-T-uptake or MTT-conversion. PGD2 (j ), PGJ2 (m ) and
D 12-PGJ2 (d ) show distinct antiproliferative activity. Indom-
ethacin  (h ) had  no  significant  effect on  cell proliferation.
Experiments  were  performed  in  quadruplicates  (mean  ±
SD).The  metabolites  PGJ2 and  D 12-PGJ2 were  about
equipotent to PGD2 in their anti-proliferative activity
on myelocytic, mastocytic, monocytic/histiocytic and
lymphocytic cells (Table 1, Fig. 4). PGD2, PGJ2 and
D 12-PGJ2 had  distinct  antiproliferative  effects  with
IC50 values ranging from 2.5 to 80m M. The metabo-
lism of PGD2 in culture medium (Fig. 3) and the fact
that  there  were  no  significant  differences  in  the
antiproliferative effects of PGD2, PGJ2 and D 12-PGJ2 in
the proliferation assays using incubation times of 24h
(Table 1, Fig. 4) are both in line with the suggestion of
Narumiya  and  Fukushima1,15,  that  D 12-PGJ2 is  the
active metabolite of PGD2 and that PGD2 may exert
no growth inhibition by itself.
The mechanism of action of D 12-PGJ2 is not fully
understood. There are no surface receptors. The lipid
mediator is actively transported into cells through a
temperature-dependent transporter on plasma mem-
branes. D 12-PGJ2 accumulates in the nuclei, where it
binds to thiol groups of nuclear proteins.16
Gluthatione  depletion  enhances  antiproliferative
activity of PGJ2 and D 12-PGJ2.14 Recently it has been
shown that intracellular glutathione modulates induc-
tion of apoptosis by D 12-PGJ2.17
PGD2 and its metabolites exerted a more distinct
antiproliferative  effect  in  lymphocytic,  myelocytic
and mast cells than in monocytic or histiocytic cells.
Primary murine BMMC were more resistant to growth
inhibition  by  PGD2,  PGJ2 or  D 12-PGJ2 than  IL-
3-dependent and autonomous mast cell lines (Table
1).  Indomethacin had  no effect  on proliferation  of
BMMC, U937 or HL-60 cells in the proliferation assays
used.
We conclude that measurement of PGD2 disregard-
ing its conversion to metabolites may grossly under-
estimate PGD2 production and effects related to these
mediators. Our results suggest that the total of PGD2,
PGJ2 and D 12-PGJ2 produced by stimulated mast cells
may be expected to exert significant antiproliferative
activity. Production of antiproliferative PGD2 metabo-
lites by BMMC in vitro raises the possibility that mast
cells  exert  an  anti-proliferative  and  anti-neoplastic
activity  by  the  release  of  anti-proliferative  PGD2
metabolites in vivo.
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